PAC-1 (Synonyms: Procaspase activating compound 1) |
カタログ番号GC11993
One-Click Copy Product Info
|
in vitroでのプロカスパーゼ-3活性化剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 315183-21-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PAC-1 is an orally active small-molecule procaspase-3 activator that induces cancer cell apoptosis with an EC50 of 2.08μM. PAC-1 can be used in the research of malignant tumors and hematologic cancers[1-4].
In vitro, PAC-1 (10–50μM) was added to HeLa cervical cancer cells for 15min, significantly reduced the intracellular free Zn²⁺ concentration, triggered endoplasmic reticulum (ER) Ca²⁺ release, and increased the cytoplasmic Ca²⁺ concentration. PAC-1 (25μM) was applied to U-937 lymphoma cells or HL-60 leukemia cells for 6h, significantly upregulating the expression of genes such as DDIT4, JUN, ATF3, and TNF, thereby inducing apoptosis. PAC-1 (100μM) was administered to U-937 lymphoma cells for 1–3h or to HeLa cells for 15–60min, which significantly induced ER stress and mitochondrial morphological speckling, downregulated TNF expression, and triggered cell death[5]. PAC-1 (1–30μM) was incubated with UMR106 osteosarcoma-like cells for 24h, significantly upregulating Fgf23 gene expression while reducing cell proliferation and viability[6].
In vivo, PAC-1 (0.15, 1.5, or 15nmol/site; single) was subcutaneously injected into the periorbital region of C57BL/6J mice. PAC-1 significantly induced dose-dependent and sustained periorbital mechanical allodynia[7]. PAC-1 (50mg/kg; once daily) was intraperitoneally injected into SCID or Balb/c nude mice bearing human breast cancer (MDA-MB-435), liver cancer (Hep3B), or gallbladder cancer (GBC-SD) xenografts for 30 days. PAC-1 significantly inhibited the in vivo growth of these tumors, which highly expressed procaspase-3[8].
References:
[1] Seervi M, Sobhan PK, Joseph J, et al. ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1). Cell Death Dis. 2013 Dec 19;4(12):e968.
[2] Putt KS, Chen GW, Pearson JM, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50.
[3] Rees TA, Labastida-Ramírez A, Rubio-Beltrán E. Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research. Trends Pharmacol Sci. 2023 Oct;44(10):651-663.
[4] Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64.
[5] West DC, Qin Y, Peterson QP, et al. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Mol Pharm. 2012 May 7;9(5):1425-34.
[6] Münz S, Feger M, Edemir B, et al. Up-Regulation of Fibroblast Growth Factor 23 Gene Expression in UMR106 Osteoblast-like Cells with Reduced Viability. Cells. 2021 Dec 23;11(1):40.
[7] De Logu F, Landini L, Janal MN, et al. Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019 Feb 14;20(1):18.
[8] Wang F, Wang L, Zhao Y, et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Mol Oncol. 2014 Dec;8(8):1640-52.
| Cell experiment [1]: | |
Cell lines | UMR106 cells (rat osteoblast-like cell line) |
Preparation Method | UMR106 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 25mM glucose and 1mM pyruvate, supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, and 100μg/mL streptomycin at 37°C, 5% CO₂. After seeding into 6-well plates for 24h, UMR106 cells were treated with PAC-1 (1-10μM) for 24 hours. |
Reaction Conditions | 1-10μM; 24h |
Applications | PAC-1 significantly up-regulated Fgf23 gene expression in UMR106 cells. PAC-1 also reduced cell proliferation and viability in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | 7- to 8-week old male SCID mice and Balb/c nude mice bearing human tumor xenografts (MDA-MB-435 breast cancer, Hep3B liver cancer, GBC-SD gallbladder cancer, or MCF-7 breast cancer). |
Preparation Method | When the average subcutaneous tumor volume reached approximately 100mm³, mice were randomly divided into treatment and control groups (eight mice per group). PAC-1 was administered via intraperitoneal injection once daily for a period of two to four weeks. Mice were subsequently sacrificed, and tumors were excised and stored at -80°C for further analysis. |
Dosage form | 50mg/kg; i.p.; once daily for 30 days |
Applications | PAC-1 significantly inhibited the in vivo growth of MDA-MB-435, Hep3B, and GBC-SD xenograft tumors which overexpress procaspase-3. Conversely, PAC-1 had no effect on the growth of MCF-7 xenograft tumors, which do not express procaspase-3. The administration of PAC-1 did not induce substantial weight loss but was associated with signs of neurotoxicity (ataxia) at high doses. |
References: | |
| Cas No. | 315183-21-2 | SDF | |
| 同義語 | Procaspase activating compound 1 | ||
| Chemical Name | 2-(4-benzylpiperazin-1-yl)-N'-[(Z)-(6-oxo-5-prop-2-enylcyclohexa-2,4-dien-1-ylidene)methyl]acetohydrazide | ||
| Canonical SMILES | C=CCC1=CC=CC(=CNNC(=O)CN2CCN(CC2)CC3=CC=CC=C3)C1=O | ||
| Formula | C23H28N4O2 | M.Wt | 392.49 |
| 溶解度 | ≥ 13.4mg/mL in DMSO, ≥ 6.87 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5478 mL | 12.7392 mL | 25.4784 mL |
| 5 mM | 509.6 μL | 2.5478 mL | 5.0957 mL |
| 10 mM | 254.8 μL | 1.2739 mL | 2.5478 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)